Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
US MFN Could Steer Clinical Trials Away from Japan: MHLW Bureau Chief
Japan faces the risk of missing out on clinical trials if the US most-favored-nation (MFN) drug pricing policy makes pharmaceutical companies more cautious about bringing new medicines to the country, a senior health ministry official has warned. “If pharmaceutical companies…
To read the full story
REGULATORY
- Suspected Drug Promotion Violations Hit Record Low in FY2025: MHLW
September 1, 2026
- Tukysa, Sohonos Now Contraindicated for Concomitant Use
September 1, 2026
- Cabinet Office Seeks 22 Billion Yen for Clinical Trial Subsidies
September 1, 2026
- Japan Healthcare Spending Hits Record 49 Trillion Yen in FY2025
September 1, 2026
- US MFN Could Steer Clinical Trials Away from Japan: MHLW Bureau Chief
September 1, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…